539 related articles for article (PubMed ID: 21577245)
21. Barrett's esophagus surveillance in a prospective Dutch multi-center community-based cohort of 985 patients demonstrates low risk of neoplastic progression.
Klaver E; Bureo Gonzalez A; Mostafavi N; Mallant-Hent R; Duits LC; Baak B; Böhmer CJM; van Oijen AHAM; Naber T; Scholten P; Meijer SL; Bergman JJGHM; Pouw RE;
United European Gastroenterol J; 2021 Oct; 9(8):929-937. PubMed ID: 34228885
[TBL] [Abstract][Full Text] [Related]
22. Risk for esophageal neoplasia in Barrett's esophagus patients with mucosal changes indefinite for dysplasia.
Horvath B; Singh P; Xie H; Thota PN; Allende DS; Pai RK; Patil DT; Plesec TP; Goldblum JR; Liu X
J Gastroenterol Hepatol; 2015 Feb; 30(2):262-7. PubMed ID: 25087917
[TBL] [Abstract][Full Text] [Related]
23. Patients With Barrett's Esophagus and Confirmed Persistent Low-Grade Dysplasia Are at Increased Risk for Progression to Neoplasia.
Duits LC; van der Wel MJ; Cotton CC; Phoa KN; Ten Kate FJW; Seldenrijk CA; Offerhaus GJA; Visser M; Meijer SL; Mallant-Hent RC; Krishnadath KK; Pouw RE; Tijssen JGP; Shaheen NJ; Bergman JJGHM
Gastroenterology; 2017 Apr; 152(5):993-1001.e1. PubMed ID: 28012849
[TBL] [Abstract][Full Text] [Related]
24. Dysplasia and risk of further neoplastic progression in a regional Veterans Administration Barrett's cohort.
Dulai GS; Shekelle PG; Jensen DM; Spiegel BM; Chen J; Oh D; Kahn KL
Am J Gastroenterol; 2005 Apr; 100(4):775-83. PubMed ID: 15784018
[TBL] [Abstract][Full Text] [Related]
25. Yield of Repeat Endoscopy in Barrett's Esophagus with No Dysplasia and Low-Grade Dysplasia: A Population-Based Study.
Visrodia K; Iyer PG; Schleck CD; Zinsmeister AR; Katzka DA
Dig Dis Sci; 2016 Jan; 61(1):158-67. PubMed ID: 25956705
[TBL] [Abstract][Full Text] [Related]
26. Persistent confirmed low-grade dysplasia in Barrett's esophagus is a risk factor for progression to high-grade dysplasia and adenocarcinoma in a US Veterans cohort.
Song KY; Henn AJ; Gravely AA; Mesa H; Sultan S; Shaheen NJ; Shaukat A; Hanson BJ
Dis Esophagus; 2020 Mar; 33(2):. PubMed ID: 31274147
[TBL] [Abstract][Full Text] [Related]
27. Barrett's esophagus and adenocarcinoma risk: the experience of the North-Eastern Italian Registry (EBRA).
Rugge M; Zaninotto G; Parente P; Zanatta L; Cavallin F; Germanà B; Macrì E; Galliani E; Iuzzolino P; Ferrara F; Marin R; Nisi E; Iaderosa G; Deboni M; Bellumat A; Valiante F; Florea G; Della Libera D; Benini M; Bortesi L; Meggio A; Zorzi MG; Depretis G; Miori G; Morelli L; Cataudella G; d'Amore ES; Franceschetti I; Bozzola L; Paternello E; Antonini C; Di Mario F; Dal Bò N; Furlanetto A; Norberto L; Polese L; Iommarini S; Farinati F; Battaglia G; Diamantis G; Realdon S; Guido E; Mastropaolo G; Canova D; Guerini A; Franceschi M; Zirillo M
Ann Surg; 2012 Nov; 256(5):788-94; discussion 794-5. PubMed ID: 23095623
[TBL] [Abstract][Full Text] [Related]
28. p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: immunohistochemical marker predictive of progression.
Weston AP; Banerjee SK; Sharma P; Tran TM; Richards R; Cherian R
Am J Gastroenterol; 2001 May; 96(5):1355-62. PubMed ID: 11374668
[TBL] [Abstract][Full Text] [Related]
29. A Tissue Systems Pathology Test Detects Abnormalities Associated with Prevalent High-Grade Dysplasia and Esophageal Cancer in Barrett's Esophagus.
Critchley-Thorne RJ; Davison JM; Prichard JW; Reese LM; Zhang Y; Repa K; Li J; Diehl DL; Jhala NC; Ginsberg GG; DeMarshall M; Foxwell T; Jobe BA; Zaidi AH; Duits LC; Bergman JJ; Rustgi A; Falk GW
Cancer Epidemiol Biomarkers Prev; 2017 Feb; 26(2):240-248. PubMed ID: 27729357
[TBL] [Abstract][Full Text] [Related]
30. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus.
Kastelein F; Biermann K; Steyerberg EW; Verheij J; Kalisvaart M; Looijenga LH; Stoop HA; Walter L; Kuipers EJ; Spaander MC; Bruno MJ;
Gut; 2013 Dec; 62(12):1676-83. PubMed ID: 23256952
[TBL] [Abstract][Full Text] [Related]
31. Complete Barrett's eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma--an American single-center experience.
Chennat J; Konda VJ; Ross AS; de Tejada AH; Noffsinger A; Hart J; Lin S; Ferguson MK; Posner MC; Waxman I
Am J Gastroenterol; 2009 Nov; 104(11):2684-92. PubMed ID: 19690526
[TBL] [Abstract][Full Text] [Related]
32. Advanced pathology under squamous epithelium on initial EMR specimens in patients with Barrett's esophagus and high-grade dysplasia or intramucosal carcinoma: implications for surveillance and endotherapy management.
Chennat J; Ross AS; Konda VJ; Lin S; Noffsinger A; Hart J; Waxman I
Gastrointest Endosc; 2009 Sep; 70(3):417-21. PubMed ID: 19555948
[TBL] [Abstract][Full Text] [Related]
33. Increasing prevalence of high-grade dysplasia and adenocarcinoma on index endoscopy in Barrett's esophagus over the past 2 decades: data from a multicenter U.S. consortium.
Desai M; Lieberman DA; Kennedy KF; Hamade N; Thota P; Parasa S; Gorrepati VS; Bansal A; Gupta N; Gaddam S; Young PE; Mathur S; Moawad FJ; Cash BD; Sampliner R; Vargo JJ; Falk GW; Sharma P
Gastrointest Endosc; 2019 Feb; 89(2):257-263.e3. PubMed ID: 30342028
[TBL] [Abstract][Full Text] [Related]
34. Patients With Barrett's Esophagus and Persistent Low-grade Dysplasia Have an Increased Risk for High-grade Dysplasia and Cancer.
Kestens C; Offerhaus GJ; van Baal JW; Siersema PD
Clin Gastroenterol Hepatol; 2016 Jul; 14(7):956-962.e1. PubMed ID: 26748222
[TBL] [Abstract][Full Text] [Related]
35. [The influence of Barrett's esophagus on the clinical signs and postoperative results of GERD].
Endzinas Z; Mickevicius A; Kiudelis M
Zentralbl Chir; 2004 Apr; 129(2):99-103. PubMed ID: 15106039
[TBL] [Abstract][Full Text] [Related]
36. Low Risk of High-Grade Dysplasia or Esophageal Adenocarcinoma Among Patients With Barrett's Esophagus Less Than 1 cm (Irregular Z Line) Within 5 Years of Index Endoscopy.
Thota PN; Vennalaganti P; Vennelaganti S; Young P; Gaddam S; Gupta N; Lieberman D; Sampliner R; Falk GW; Mathur S; Kennedy K; Cash BD; Moawad F; Bansal A; Spaander MC; Bruno MJ; Vargo J; Sharma P
Gastroenterology; 2017 Apr; 152(5):987-992. PubMed ID: 27988383
[TBL] [Abstract][Full Text] [Related]
37. Barrett's surveillance identifies patients with early esophageal adenocarcinoma.
Wong T; Tian J; Nagar AB
Am J Med; 2010 May; 123(5):462-7. PubMed ID: 20399324
[TBL] [Abstract][Full Text] [Related]
38. Management of low-grade dysplasia in Barrett's esophagus.
Wani S
Curr Opin Gastroenterol; 2012 Jul; 28(4):370-6. PubMed ID: 22508323
[TBL] [Abstract][Full Text] [Related]
39. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus.
Kastelein F; Spaander MC; Biermann K; Steyerberg EW; Kuipers EJ; Bruno MJ;
Gastroenterology; 2011 Dec; 141(6):2000-8; quiz e13-4. PubMed ID: 21878200
[TBL] [Abstract][Full Text] [Related]
40. Barrett's esophagus: a retrospective analysis of 13 years surveillance.
Switzer-Taylor V; Schlup M; Lübcke R; Livingstone V; Schultz M
J Gastroenterol Hepatol; 2008 Sep; 23(9):1362-7. PubMed ID: 18205769
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
